

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Ivosidenib for treating advanced cholangiocarcinoma  
with an IDH1 mutation after at least 1 therapy [ID6164]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final draft guidance**

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

None identified.
------------------

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No other equality issues were identified.
---

- |  |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No other equality issues were identified.
---

- |  |
|--|
| 4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
|--|

No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Yes, in section 3.16

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 30 November 2023